Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

NCT06200974 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06200974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06200974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2024
Completion date
February 1, 2038
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

localized prostate carcinoma